Molecure - Novel approaches for problematic diseases
Molecure aims to discover and develop drugs that have novel mechanisms of action to address serious unmet medical needs. Its two lead assets, OATD-01 and OATD-02, are approaching important clinical development milestones. After a strategic decision by partner Galapagos (June 2022), the rights to OATD-01 were returned to the company. Molecure now plans to leverage newly collected data to commence a Phase II trial in sarcoidosis in mid-2023, with top-line results expected in Q125. In addition, management anticipates OATD-02 could enter Phase I trials in solid tumour indications in Q422, subject to regulatory approval. With a cash position of PLN80.7m at end-September 2022, the company guides that its current runway is into Q224.OncoArendi Therapeutics SA (OAT) is a Poland-based biopharmaceutical company dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Companys business model is strictly focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations with the key opinion leaders in specific disease areas.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.